Welcome to our dedicated page for Surrozen, Inc./DE SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Surrozen, Inc./DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Surrozen, Inc./DE's regulatory disclosures and financial reporting.
Surrozen, Inc. files its annual report describing a shift to an ophthalmology-focused pipeline built on Wnt-pathway modulation. The company highlights preclinical eye candidates SZN-8141 and SZN-8143 for diabetic macular edema, wet age-related macular degeneration and uveitic macular edema, all based on its SWAP antibody platform.
Surrozen’s Fzd4-targeted antibody SZN-413 is partnered with Boehringer Ingelheim; Boehringer’s 2024 advancement decision triggered a $10.0 million milestone, and a 2026 toxicology milestone entitles Surrozen to an additional $5.0 million. The company also discontinued liver candidate SZN-043 in severe alcohol-associated hepatitis to focus resources on eye diseases.
Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.
Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.
Surrozen, Inc. (SRZN) reported insider buying by affiliated investment funds. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% holders, executed a series of open-market purchases of Common Stock on March 12–16, 2026, totaling 48,997 shares according to the filing’s transaction summary.
The trades were made at prices between 24.8769 and 24.9857 per share and are reported as indirect holdings. TCG Crossover GP II, LLC and TCG Crossover GP III, LLC act as general partners to the funds, and Chen Yu may be deemed to share voting, investment and dispositive power over these securities.
Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.
The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.
Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.
Surrozen, Inc. reported that Chief Executive Officer Craig C. Parker received new equity awards. On February 17, 2026, he was granted an employee stock option covering 242,200 shares of common stock at an exercise price of $0.0000 per share, held as direct ownership.
The option vests over four years in 48 equal monthly installments starting from February 1, 2026, conditioned on continued service. Parker was also granted 242,200 restricted stock units, each representing one share of common stock. These RSUs vest in four equal annual installments beginning on February 1, 2026, also subject to continued service.
Braidwell and affiliates disclosed a significant position in Surrozen, Inc. common stock. As of December 31, 2025, Braidwell LP, Braidwell Management LLC, Alexander T. Karnal, and Brian J. Kreiter may be deemed beneficial owners of 470,000 shares, representing about 5.5% of Surrozen’s outstanding common stock.
All 470,000 shares are directly owned by Braidwell Partners Master Fund LP, with each reporting person sharing voting and dispositive power and no sole authority. The stake is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. received an updated ownership report showing that RA Capital Management, its affiliated fund, and principals Peter Kolchinsky and Rajeev Shah collectively report beneficial ownership of 871,731 shares of common stock, representing 9.2% of the class as of December 31, 2025.
The position includes Series A warrants for up to 322,580 shares, Series B warrants for up to 350,876 shares, and Series E warrants for up to 198,275 shares of common stock. The filing states the securities are not held for the purpose of changing or influencing control of Surrozen.
StemPoint Capital and related parties reported a significant ownership stake in Surrozen, Inc. The Schedule 13G/A shows StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross collectively beneficially owning 619,766 shares of Surrozen common stock, including 329,658 shares issuable upon exercise of warrants.
This represents 7.0% of Surrozen’s common stock, calculated using 8,571,421 shares outstanding as of November 5, 2025, plus specified Series A, B, and E warrants subject to a 9.9% beneficial ownership limitation. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico filed an amended Schedule 13G reporting beneficial ownership of 316,289 shares of Surrozen, Inc. common stock, representing 3.6% of the class as of the reported date.
The stake consists of 113,631 shares of common stock plus 202,658 shares issuable upon exercise of Series A, Series B and Series E warrants, all subject to a 9.9% beneficial ownership limitation. The percentage is based on 8,571,421 shares outstanding as of November 5, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control.